Neuron23 Collaborated with QIAGEN to Develop CDx for LRRK2 inhibitor to Treat Parkinson's Disease
Shots:
- QIAGEN will focus on developing & validating a clinical trial assay to detect biomarkers being discovered by Neuron23 for LRRK2 inhibitor (currently in late stages of preclinical development) in Parkinson's disease. The collaboration will support the clinical development of the LRRK2 inhibitor
- The collaboration will combine the expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN's CDx development. The collaboration will also advance QIAGEN’s NGS testing portfolio for precision medicine beyond oncology into neurology applications
- The alliance will also cover the future development of additional CDx & will submit the application to the US FDA for PMA of the NGS CDx test & NDA for the LRRK2 inhibitor
Ref: PRNewswire | Image: QIAGEN
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
